SGC-iMLLT

CAS No.

SGC-iMLLT ( —— )

Catalog No. M17063 CAS No.

SGC-iMLLT is the first small molecule chemical probe for the YD of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3) with Kd of 129 and 77 nM respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity

Biological Information

  • Product Name
    SGC-iMLLT
  • Note
    Research use only, not for human use.
  • Brief Description
    SGC-iMLLT is the first small molecule chemical probe for the YD of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3) with Kd of 129 and 77 nM respectively.
  • Description
    SGC-iMLLT is the first small molecule chemical probe for the YD of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3) with Kd of 129 and 77 nM respectively, IC50 of 0.26 uM (MLLT1); SGC-iMLLT is a potent and selective inhibitor of MLLT1/3-histone interaction; dsiplays excellent selectivity over other human YD proteins (YEATS2/4) and bromodomains.
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Bromodomain
  • Recptor
    Bromodomain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    --
  • Formula Weight
    388.48
  • Molecular Formula
    C22H24N6O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(C1=CC2=C(N(C)N=C2)C=C1)NC3=CC=C4NC(CN5[C@@H](C)CCC5)=NC4=C3
  • Chemical Name
    (S)-1-methyl-N-(2-((2-methylpyrrolidin-1-yl)methyl)-1H-benzo[d]imidazol-5-yl)-1H-indazole-5-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Moustakim M, et al. Angew Chem Int Ed Engl. 2018 Oct 5. doi: 10.1002/anie.201810617.
molnova catalog
related products
  • IACS-7e

    IACS-7e is a potent TRIM24 bromodomain inhibitor with IC50 of 217.8 nM (TRIM24 ligand displacement).

  • BI-7273

    A potent, selective and cell-permeable BRD9 bromodomain inhibitor with IC50 of 19 nM in Alpha assay.

  • INCB054329

    INCB054329 is a novel potent, orally bioactive BET inhibitor that inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency.